This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Digging through decades of data from PubMed, Embase, and ClinicalTrials.gov, researchers pooled all relevant articles published through June 2024 (108k patients) and found that a combination lipid-lowering therapy (LLT) of statins plus ezetimibe led to significantly better CV outcomes compared to statin monotherapy.
tim.hodson Tue, 12/03/2024 - 16:52 Nov. 18, 2024 — In November, Esperion presented an analysis from the CLEAR Outcomes study focused on patients with Peripheral Artery Disease (PAD) who were unable or unwilling to take statin medications. It was presented on behalf of all authors by Marc P. Bempedoic acid reduced MALE (e.g.
tim.hodson Fri, 11/08/2024 - 10:10 Medtronic recently announced results from two studies evaluating the utility of atherectomy for peripheral endovascular interventions. Results from both analyses were released at the Vascular InterVentional Advances (VIVA) 2024 conference in Las Vegas.
As we step into 2024, the field of cardiology continues to offer exciting opportunities for knowledge exchange and networking at in-person conferences. Here is a preview of the upcoming cardiology conferences planned for 2024. Fees: Visit the ESC ACVC 2024 website for registration options. Hashtag: #ACVC2024 2.
Our March 2024 month-in-review in hematology features updates to the anemia pipeline, the latest research in sickle cell disease, and the role of SGLT2 inhibition on hematologic outcomes.
June 4, 2024 — The countdown has begun ahead of the American Society of Echocardiography 35th Annual ASE Scientific Sessions, June 14-26, at the Oregon Convention Center in Portland, OR. The Program Chair for ASE 2024 is Federico Asch, MD, FASE, MedStar Health and Georgetown University (Wash.,
Innovation in medical technology exists to improve patient outcomes, increase surgical efficiency and enhance patient safety. The expo floor was a veritable candy store for the scientifically minded electrophysiologist, with displays of wares that promised to improve the clinician’s outcomes.
milla1cf Wed, 05/15/2024 - 19:05 May 15, 2024 — CardioFocus, Inc. , a medical device company dedicated to advancing ablation treatment for cardiac arrythmias, announced its participation at the Heart Rhythm 2024 conference, taking place in person at the Boston Convention & Exhibition Center and virtually, May 16-19, 2024.
mtaschetta-millane Thu, 07/25/2024 - 08:55 July 25, 2024 — Nanox, an innovative medical imaging technology company, announced that the AI Cardiac Solution (HealthCCSng) of its subsidiary, Nanox.AI was highlighted in multiple scientific presentations at the 2024 Society of Cardiovascular Computed Tomography (SCCT) Annual Meeting. “We
The Heart Rhythm Society (HRS) is preparing for HRX 2024, the third annual event of its kind, which will be held from September 5-7, 2024, in Atlanta, GA, gathering cardiovascular health innovators together to explore discoveries and advance partnerships between medicine and technology. On Thursday, Sept. On Thursday, Sept.
milla1cf Mon, 01/29/2024 - 11:00 January 29, 2024 — The Society of Thoracic Surgeons has released late-breaking research scheduled for presentation at the 2024 Annual Meeting taking place January 27 - 29 in San Antonio.
mtaschetta-millane Thu, 06/20/2024 - 08:32 June 19, 2024 — Royal Philips , a global leader in health technology, today announced the launch of Philips Image Guided Therapy Mobile C-arm System 9000 – Zenition 90 Motorized , designed to help clinicians deliver high-quality care to more patients.
In a recent study published in the European Heart Journal, researchers investigated the influence of varying degrees and extent of untreated chronic obstructive CAD on TAVR outcomes and longer-term results. European Heart Journal 2024. The post Impact of untreated CAD on TAVR outcomes appeared first on Cardiology Update.
milla1cf Tue, 02/13/2024 - 17:52 February 13, 2024 — RapidAI , the global leader in developing Artificial Intelligence ( AI ) and clinical workflow solutions to combat life-threatening neurovascular, cardiac, and vascular diseases, today announced the publication of the TIMELESS trial in the New England Journal of Medicine (NEJM).
Pankaj Garg, MD mtaschetta-millane Fri, 07/12/2024 - 11:14 July 12, 2024 — Researchers have developed a groundbreaking method for analyzing heart MRI scans with the help of artificial intelligence , which could save valuable NHS time and resources, as well as improve care for patients.
milla1cf Tue, 03/26/2024 - 13:00 March 26, 2024 — Esperion announced the acceptance of three CLEAR ( C holesterol L owering via B e mpedoic acid, an A CL-Inhibiting R egimen ) Outcomes subgroup analyses as poster presentations at th e 2024 American College of Cardiology’s Annual Scientific Session ( ACC.24
Excellent clinical outcomes were observed in patients managed with HeartCare including fewer follow-up endomyocardial biopsies, 95% survival and 97% with normal allograft function at two years post-transplantation. Hanna , CareDx President and CEO.
Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta-analysis. To address these inconsistencies, the present meta-analysis aimed to evaluate the association of CH with the incidence and clinical outcomes of HF. Clonal haematopoiesis and heart failure: a meta-analysis.
Getty Images milla1cf Mon, 01/29/2024 - 14:24 January 29, 2024 — Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under age 65 with severe aortic stenosis , many hospitals are still opting for a nonsurgical approach in patients under 60—possibly with poorer survival rates.
An EADV 2024 study suggests dupilumab use during pregnancy is generally safe and may lower risks of preterm labor, gestational hypertension, and diabetes.
We wanted to examine our outcomes, and we were pleasantly surprised to find that the freedom from re-intervention was 91% at 10 years and 87% at 20 years. Congenital All Members Clinical Decision-Making Patient Outcomes Quality Improvement The main drawback of the Ross operation is failure of the autograft over time, Dr. Shetty said.
Findings from the highly-anticipated MOST (Multi-Arm Optimization of Stroke Thrombolysis) trial were presented on the first day of the American Stroke Association’s International Stroke Conference, ISC 2024, being held through Feb. The study was looking for improvement in functional outcomes at 90 days. 9 Phoenix, AZ. Adeoye, M.D.,
Now, we have a well-validated, non-invasive tool to monitor organ rejection and injury, which has the potential to improve their quality of life and long-term outcomes. "We In 2024, over 4,500 heart transplants were performed in the U.S. 8 Additionally, in 2024 more than 700 patients received an SPK transplant. Clin Transplant.
3) We do not show the upward concavity measurement technique here. == MY Comment , by K EN G RAUER, MD ( 11/27 /2024 ): == For optimally time-efficient identification of acute OMI in the absence of frank ST elevation — it's essential to get good at recognizing hyperacute T waves. "A A picture is worth 1,000 words".
With OTC approval, these devices are now more accessible to a broader range of patients, empowering people to understand the impact of diet and potentially improving health outcomes. Libre Rio CGM System The Libre Rio CGM system, also FDA approved on June 10, 2024, is renowned for its accuracy and affordability.
This September 2024 month in review highlights recent advances in gene therapies and therapies demonstrating the potential for improved vision outcomes.
The second quarterly issue of 2024 reviews outcomes in liver disease after bariatric surgery, glucagon’s role in esophageal impaction management, and outcomes after cuffitis following pouch creation.
Bob Ross, PA-C, shares expert insights on early PAD detection, updated guidelines, and practical tools to improve vascular health outcomes from CAPP 2024.
They concluded, "Our findings increase confidence in the normal automated GE Marquette 12 SL ECG software interpretation to predict a benign outcome. Smith comment: this is a very stupid outcome measure) What if we use that methodology for the ECG above? What is the gold standard for ECG interpretation: patient outcome!!!
Demographic, clinical, and diagnostic data, as well as follow-up outcomes, were reviewed. Patients with RP-HCM showed the poorest outcomes, with a follow-up mortality rate of 42.86%. Only 10.4% (22/212) of patients underwent genetic testing, yet the positive detection rate was 63.7% (14/22).ConclusionsThis
milla1cf Thu, 04/04/2024 - 12:16 April 4, 2024 — Viz.ai , a leader in AI-powered disease detection and intelligent care coordination, announced new clinical data supporting advancements in cardiology care. The Viz HCM module is the first and only AI algorithm cleared by the FDA for HCM. “At
The 2025 AHA Statistical Update is the product of a full years worth of effort in 2024 by dedicated volunteer clinicians and scientists, committed government professionals, and AHA staff members.
The 2024 AHA Statistical Update is the product of a full year’s worth of effort in 2023 by dedicated volunteer clinicians and scientists, committed government professionals, and AHA staff members.
Publication date: Available online 14 November 2024 Source: The American Journal of Cardiology Author(s): Pedro Arturo Villablanca, Raef Ali Fadel, Gennaro Giustino, Ahmad Jabri, Mir Babar Basir, Jennifer Cowger, Khaldoon Alaswad, Brian O'Neill, Pedro Engel Gonzalez, Gillian Grafton Gyzm, Tiberio Frisoli, James Lee, Lindsey Aurora, Sarah Gorgis, Hassan (..)
Cardiopulmonary bypass ensured safe manipulation, and post-operative imaging confirmed excellent outcomes, with complete symptom resolution. Advances in imaging and surgical techniques, including hybrid methods, have improved outcomes, with mortality rates significantly lower than historical benchmarks.
The third quarterly issue of 2024 reviews early versus late ERCP outcomes post-transplant, the impact of GLP-1RA use on endoscopic management, and the differential diagnosis of seronegative villous atrophy.
Nature Reviews Cardiology, Published online: 19 September 2024; doi:10.1038/s41569-024-01087-x The non-steroidal mineralocorticoid receptor antagonist finerenone reduces the risk of adverse outcomes in patients with heart failure with mildly reduced ejection fraction or with preserved ejection fraction, according to findings presented at the ESC Congress (..)
A total of 9,905 publications from 67 countries were published from 1 January 2014, to 1 March 2024. A total of 2,142 (29.52%) studies were from the United States, 1,293 (13.05%) were from China, and 919 (9.28%) were from the United Kingdom. Abdominal aortic aneurysm was the most frequently used author keyword (2,492).
IntroductionDepression is a significant comorbidity linked to poor subjective and objective health outcomes in cardiac patients. The paucity of data necessitates further research to elucidate the pathophysiological connection between depression and cardiac diseases in the presence of N-terminal pro-brain natriuretic peptide (NT-proBNP).
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content